Roivant Sciences Limited header image

Roivant Sciences Limited

ROIV

Equity

ISIN BMG762791017 / Valor 113331044

NASDAQ (2026-06-26)
USD 34.07+0.15%

Roivant Sciences Limited
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Roivant Sciences Limited is a biopharmaceutical company that focuses on developing and commercializing innovative therapies by leveraging technology to enhance drug development processes. The company aims to transform the pharmaceutical industry by integrating technology and data analytics into its operations, positioning itself as a pioneering PharmaTech entity. Roivant operates through a unique model of creating subsidiary companies, known as "Vants," each dedicated to specific therapeutic areas or technologies. This approach allows Roivant to efficiently manage and advance a diverse portfolio of drug candidates across various stages of development. The company is known for its strategic partnerships and collaborations, which help accelerate the development and commercialization of its therapies. Roivant's business strategy is centered on addressing unmet medical needs and improving patient outcomes through the application of cutting-edge technology and innovative drug development methodologies.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

194%1Y
271%3Y
244%5Y

Performance

40.1%1Y
41.2%3Y
57.6%5Y

Volatility

Market cap

24506 M

Market cap (USD)

Daily traded volume (Shares)

12,406,498

Daily traded volume (Shares)

1 day high/low

11.78 / 11.37

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Poly Medicure Limited
Poly Medicure Limited Poly Medicure Limited Valor: 26795477
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.04%INR 1,650.30
Rubicon Research Limited
Rubicon Research Limited Rubicon Research Limited Valor: 149582844
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.39%INR 1,416.45
Fresenius Medical Care AG
Fresenius Medical Care AG Fresenius Medical Care AG Valor: 523134
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.04%USD 23.24
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.62%USD 24.29
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.60%USD 20.94
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.79%USD 70.24
LivaNova PLC
LivaNova PLC LivaNova PLC Valor: 28726218
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.94%USD 83.43
TransMedics Group Inc
TransMedics Group Inc TransMedics Group Inc Valor: 47361695
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-11.97%USD 68.44
Kenvue Inc
Kenvue Inc Kenvue Inc Valor: 124280948
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.90%USD 19.13
Alignment Healthcare Inc
Alignment Healthcare Inc Alignment Healthcare Inc Valor: 110387702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.11%USD 23.19